BRIEF-IDMC Recommends Continuation Of Cytodyn's Pro 140 Pivotal Combination Therapy Trial Without Modifications
December 07, 2017 at 06:13 AM EST
* INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF CYTODYN'S PRO 140 PIVOTAL COMBINATION THERAPY TRIAL WITHOUT MODIFICATIONS
